She was losing bone mass at the rate of 5% per year while taking androgen-blockers without also taking estrogen (Hierl et al 1999). Those who wish to slow their hair loss have many options. Aug 23, 2020 - Explore Wallis Garbotz's board "Trans Women - Before and After", followed by 707 people on Pinterest. To avoid some confusion, the abbreviation for micrograms is not used in these tables. One way to gauge their reliability is to compare the concrete dosage recommendations against those provided by medical sources.I subscribed to an electronic mailing list on which transsexuals who are self-medicating (primarily MTFs) exchange advice on hormone therapy, and selected twenty-one individual posters who identified their own regimens, including drug names and dosage, and did not report dissatisfaction or ask for help in modifying their hormone regimens. Guo EL, Katta R (2017). Scalp hair loss is often a major concern for transgender women and transfeminine people. Five (25%) used an anti-androgen considered less effective by Asscheman and Gooren.
Because of the way that phytoestrogens compete with estrogen for receptors, using them in addition to hormone therapy may also be counterproductive.Combined treatment with estrogen and cyproterone acetate is associated with increases in thromboembolic events (Asscheman, Gooren, & Eklund). This information is not provided or intended as a substitute for professional medical advice or care.I am not a medical professional. Baby steps becoming giant strides. Another study of transsexual women with elevated prolactin levels “suggest that the risk of inducing prolactinomas through cross-gender hormone treatment is likely to be small.” (Gooren et al 1985)Combined treatment with estrogen and cyproterone acetate [an androgen-blocker] is associated with transient elevation of liver enzymes (Asscheman, Gooren, & Eklund). The complications of hyperprolactinemia are limited, but can include blindness and hemorraging (Schenenberger & Knee 2001). Check out www.hair-removalpro.com to find out different methods of hair removal Transgender hormone therapy of the male-to-female (MTF) type, also known as transfeminine hormone therapy, is hormone therapy and sex reassignment therapy to change the secondary sexual characteristics of transgender people from masculine or androgynous to feminine. Self-Assessments of Standardized
Included in the numbers already reported, four (19%) used lower than recommended doses of both the anti-androgen and estrogen. ), I started a new job en femme and I had a hair transplant. 2017 Jan; 7(1): 1–10.Published online 2017 Jan 31. (RxList). Of those, four (19%) reported hormone regimens that were within the guidelines given by Asscheman and Gooren or Lawrence.Of those who were not within the guidelines, the differences ranged from the possibly ineffective to the potentially dangerous. HRT and Hair Loss Estrogen is related to hair growth — and hair loss. The descriptions of the terms in the glossary are meant to help you interpret their use in this article only, and are not comprehensive definitions.There are no generally agreed upon recommended dosages, or recommended drugs within categories. Male to Female Transition and Self Medicating Guide. While some trans men and transmasculine people welcome scalp hair loss, others wish to avoid it. Scalp hair loss is often a major concern for transgender women and transfeminine people. The unfortunate answer here is that while HRT may eventually cause some of your body hair to get a bit thinner lighter and softer it’s not going to completely eliminate your body hair. Three (14%) who did not report having had orchiectomies said they used no anti-androgen. The liver function issues in the 1989 study were attributed to other causes, such as alcohol abuse and hepatitis B, and were mainly successfully treated, either with other medications or temporarily halting hormone treatment.In a German case study, bone loss was reversed in an MTF woman by adding 2 mg of oral estradiol valerate daily to the 100 mg of cyproterone daily she was already taking. (Becerra Fernandez et al 1999) However, the higher levels of cholesterol and triglycerides were still within normal levels (Citkowitz 2001, Isley 2002) and the lower incidence of other factors associated with heart disease, such as elevated plasma tHcy levels (Giltay et al 1998), suggest this is an acceptable risk.Spironolactone use can cause hyperkalemia, an excessive amount of potassium in the blood. In one case study, prolactin-producing pituitary adenoma was linked with long-term estrogen use (Kovacs et al 1994). The more serious risk of thromboembolism, according to a later study by two of the same researchers, is greatly reduced by the use of transdermal estrogen therapy in patients over the age of 40, in whom “a high incidence of venous thromboembolism was observed with oral oestrogens.” (van Kesteren et al 1997) A 1998 study in which estrogen was administered by injection or orally reported incidence of thromboembolic events as “negligible” (Schlatterer et al).In a 1989 retrospective study, combined treatment with estrogen and cyproterone acetate was associated with increases in hyperprolactinemia (Asscheman, Gooren, & Eklund).